tbuckley/cabot-search huggingface dataset:
Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
Authors: D. J. Renouf, H. J. Lim, C. Speers, D. Villa, S. Gill, C. D. Blanke, S. E. O’Reilly, H. Kennecke
Journal: Journal of Clinical Oncology (2009)

4114 Background: As of 2003, irinotecan or oxaliplatin in combination with fluorouracil was standard treatment for MCRC in British Columbia (BC). The addition of bev to chemotherapy (CT) was approved in BC in 2006. We compared OS between referred pts diagnosed with MCRC in 2003/2004 (pre-bev era) and 2006 (bev era). Methods: All pts diagnosed with MCRC in 2003/04 and 2006, and referred to the BC Cancer Agency (BCCA) were included. The BCCA is a cancer network with centers throughout BC, ≈60% of MCRC pts in BC are referred to the BCCA. Systemic therapy (ST) is centrally funded and treatment data was obtained from the pharmacy database. The primary endpoint was OS of all pts within each cohort. Secondary endpoints were OS in pts treated with ST, and in those not treated. Kaplan Meier method was used for survival analysis. Subgroup analysis based on age was performed. Results: 1417 pts were included: 969 from 2003/04, and 448 from 2006. Median age at diagnosis of MCRC was 68y in 2003/04 and 69y in 2006. Median follow up time was 47.3 and 21.4 mos respectively. Between 2003/04 and 2006 the proportion of pts treated with ST for MCRC increased from 61.1% to 67.6% (p= 0.02). Proportion of pts who received irinotecan, oxaliplatin and fluorouracil did not change (24.7% to 23.7%, p=0.68). Proportion of pts who received bev increased (5.9% to 30.6%, p&lt;0.001). Median OS significantly improved for the entire cohort (13.8 to 17.3 mos, p&lt;0.001). Median OS for pts who received ST for MCRC improved (18.6 to 23.6 mos, p=0.001). Median OS for pts who did not receive ST did not change (6.1 to 5.9 mos, p=0.65). Of pts who received ST, the proportion who received bev increased in pts &lt;70 (12.7% to 58%, p&lt;0.001) and in pts ≥70 (3.6% to 22.7%, p&lt;0.001). Median OS for pts &lt;70 who received ST for MCRC improved (20.3 to 26.5 mos, p = 0.002). Median OS for pts ≥70 who received ST for MCRC improved (16.5 to 19.9 mos), but this was not significant (p=0.16). Conclusions: In this population based study, median OS for MCRC significantly increased between 2003/04 and 2006. The improvement in survival appears to be limited to pts treated with ST for metastatic disease. The main difference in ST has been the addition of bev. On a population basis, the addition of bev to CT is associated with a significant improvement in OS in MCRC. No significant financial relationships to disclose.
In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y
Authors: Michal Mazurek, Gregory Y.H. Lip
Journal: Annals of Internal Medicine (2016)

Source Citation Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. 27295427
Long-Term Experience with Anagrelide (Thromboreductin®) In the Treatment of Essential Thrombocythemia: Data from an International Registry
Authors: Michael Steurer, Heinz Gisslinger, Miroslav Penka, Siegfried Sormann, Jiri Schwarz, Elena Tothova, Mikulas Hrubisko, Andrzej Hellmann, Maria Podolak-Dawidziak, Petro E. Petrides
Journal: Blood (2010)
Letter to the editor: Regarding the editorial by Penttinen and Friede
Authors: Alicia M Fry, Brendan Flannery, Sonja J Olsen, Lisa Grohskopf, Joseph Bresee
Journal: Eurosurveillance (2016)

Preview this article: Letter to the editor: Regarding the editorial by Penttinen and Friede, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/40/eurosurv-21-30366-3-1.gif
Energy Harvesting from the Animal/Human Body for Self-Powered Electronics
Authors: Canan Dagdeviren, Zhou Li, Zhong Lin Wang
Journal: Annual Review of Biomedical Engineering (2017)

Living subjects (i.e., humans and animals) have abundant sources of energy in chemical, thermal, and mechanical forms. The use of these energies presents a viable way to overcome the battery capacity limitation that constrains the long-term operation of wearable/implantable devices. The intersection of novel materials and fabrication techniques offers boundless possibilities for the benefit of human health and well-being via various types of energy harvesters. This review summarizes the existing approaches that have been demonstrated to harvest energy from the bodies of living subjects for self-powered electronics. We present material choices, device layouts, and operation principles of these energy harvesters with a focus on in vivo applications. We discuss a broad range of energy harvesters placed in or on various body parts of human and animal models. We conclude with an outlook of future research in which the integration of various energy harvesters with advanced electronics can provide a new platform for the development of novel technologies for disease diagnostics, treatment, and prevention.
A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
Authors: D. Mavroudis, I. Boukovinas, C. Christophyllakis, N. Xenidis, P. Papakotoulas, N. A. Malamos, S. Kakolyris, A. Polyzos, V. Georgoulias
Journal: Journal of Clinical Oncology (2010)

1116 Background: Docetaxel (D) plus epirubicin (E) is highly active first-line therapy for metastatic breast cancer (MBC), with acceptable toxicity profile. The addition of bevacizumab (B) was investigated in this phase I-II study to assess the efficacy and toxicity of front-line DEB in MBC patients. Methods: Women with previously untreated HER2-negative MBC received B (15 mg/kg), E (75mg/m2) and D (75mg/m2) with prophylactic G-CSF support every 3 weeks for 6 cycles followed by B (15 mg/kg q 3w) until disease progression with primary end point objective response rate (ORR). Circulating tumor cells (CTCs) were measured in the blood using the CellSearch system before and at different time points after therapy. The study followed a two step design with toxicity and efficacy initially assessed in the first 16 patients. Results: Sixty-four women were enrolled with median age 60 years, performance status 0-1 in 92%, triple negative 11%, liver metastases 48%. In sixty evaluable patients complete response was observed in 10 (17%), partial response in 28 (47%) with ORR 64%. Estimated median time to progression was 14 months and 1 year survival 82%. Grade 3-4 neutropenia occurred in 34%, febrile neutropenia in 8%, anemia in 5%, thrombocytopenia in 3%, diarrhea in 3% of patients. There were two deaths possibly related to study treatment (sigmoid perforation n=1; sudden death n=1). In 50 patients with detectable CTCs prechemotherapy, 14 (28%) had >5CTCs/7.5ml blood and in 10 of them (71%) CTCs decreased to <5 after the first cycle. Conclusions: The DEB is an active but also potentially toxic combination in MBC and is associated with a significant decrease of the number of CTCs. No significant financial relationships to disclose.
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
Authors: Paola Neri, Nizar J. Bahlis, Sagar Lonial
Journal: Clinical Cancer Research (2016)

Abstract Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in the clinical potential of immunotherapy for the treatment of multiple myeloma. Clinical progression of myeloma is known to be associated with progressive immune dysregulation and loss of immune surveillance that contribute to disease progression in association with progressive genetic complexity, rendering signaling-based treatments less effective. A variety of strategies to reverse the multiple myeloma–induced immunosuppression has been developed either in the form of immunomodulatory drugs, checkpoint inhibitors, mAbs, engineered T cells, and vaccines. They have shown encouraging results in patients with relapsed refractory multiple myeloma and hold great promise in further improving patient outcomes in multiple myeloma. This review will summarize the major approaches in multiple myeloma immunotherapies and discuss the mechanisms of action and clinical activity of these strategies. Clin Cancer Res; 22(24); 5959–65. ©2016 AACR.
Abstract B14: Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric adenocarcinoma
Authors: Hoon Hur, In-hye Ham, Da Keun Lee, Hye-Jin Jin, Aguilera Kristina Y, Hae Jeong Oh, Sang-Uk Han, Ji-Eun Kwon, Young Bae Kim, Ke Ding, Rolf Brekken
Journal: Cancer Research (2016)

Abstract Purpose: Stromal content in gastric cancer patients inversely correlates with outcome. However, underlying molecular mechanisms for these clinical observations have not been determined. Here, we investigated the contribution of the collagen receptor, discoidin domain receptor-1 (DDR1), in the aggressive phenotype of gastric cancer induced by tumor stroma. Experimental Design: We conducted immunohistochemical analyses with a tissue microarray of 217 gastric cancer specimens. We examined the effect of collagen-induced activation of DDR1 on cell signaling, tumorigenesis and cell migration in gastric cancer, and evaluated the effects of DDR1 inhibition in organotypic culture and xenograft animal models of gastric cancer. Results: High DDR1 expression in gastric cancer tissue significantly correlated with poor prognosis. Gastric cancer patients were classified into two groups based on the stromal collagen and the expression of DDR1 was significantly associated with cancer invasion and lymph node metastasis in the collagen-positive group. Decreased expression of E-cadherin was associated with cancer progression in the collagen and DDR1 positive groups. We also demonstrated that collagen activated DDR1 and increased clonogenicity and cell migration. Importantly, we demonstrated that a DDR1 inhibitor, 7rh benzamide, reduced the invasiveness of gastric cancer in organotypic culture system and suppressed tumor growth in gastric cancer xenografts. Conclusions: Taken together, these findings suggest that collagen enhances the aggressive phenotype of gastric cancer through the DDR1 signaling pathway and that inhibition of DDR1 is an attractive candidate for the therapy of aggressive gastric cancer. Citation Format: Hoon Hur, In-hye Ham, Da Keun Lee, Hye-Jin Jin, Aguilera Kristina Y., Hae Jeong Oh, Sang-Uk Han, Ji-Eun Kwon, Young Bae Kim, Ke Ding, Rolf Brekken. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr B14.
Real-time reverse transcription-polymerase chain reaction for detection of SYT-SSX translocation in synovial sarcoma
Authors: J. Liu, K. Qu, C. Chai, H. Li, A. Sferruzza, R. A. Bender
Journal: Journal of Clinical Oncology (2006)

9553 Background: Synovial sarcoma is the most common non-rhabdomyosarcomatous soft tissue sarcoma in children and adolescents. A specific translocation, t(X;18), induces fusion of the SYT gene on chromosome 18 to an SSX gene on chromosome X. The resulting fusion gene consists of at least 2 subtypes with different breakpoints: SYT-SSX1(X;18)(p11.23;q11.2) and SYT-SSX2 (X;18)(p11.21;q11.2). Because t(X;18) transcripts occur in &gt;90% of synovial sarcoma subtypes, this marker may be useful for diagnosis. We evaluated the accuracy of a multiplex real-time reverse transcription-polymerase chain reaction (RT-PCR) assay for detection of the primary SYT-SSX fusion transcript types in formalin-fixed, paraffin-embedded (FFPE) tissues and frozen tissues. Methods: 17 tumors (7 synovial sarcomas, 4 Ewing’s sarcomas, 5 rhabdomyosarcomas, 1 small round blue-cell tumor), 4 normal tissues, and 4 control samples were tested for SYT-SSX translocations using real-time RT-PCR. Results were compared to those obtained with gel electrophoresis detection of amplified transcripts; discrepant results were confirmed by sequencing. Results: Concordance between real time RT-PCR and gel electrophoresis was 100% (25/25) for internal control genes and SYT-SSX1, and 92% (23/25) for SYT-SSX2. Of the 2 samples with discordant SYT-SSX2 results, 1 was positive by real-time RT-PCR but not gel electrophoresis and 1 was positive by electrophoresis but not real-time RT-PCR; in both cases, DNA sequencing confirmed the real-time RT-PCR results. The minimum percentage of tumor to normal cells required for detection of SYT-SSX fusion transcripts by real-time RT-PCR was 6.25%. Conclusions: This real-time RT-PCR assay appears to provide greater accuracy than gel electrophoresis for identification of SYT-SSX translocation and fusion types. No significant financial relationships to disclose.
Pattern of local failure after primary 2-dimensional radiotherapy (2DRT) in non-metastatic nasopharyngeal carcinoma patients: Predominance of within-field failure and hints on dose escalation effect
Authors: M. K. Kam, S. F. Leung, W. H. Kwan, R. M. Chau, K. Y. Cheung, K. H. Yu, S. K. Chiu, A. T. Chan
Journal: Journal of Clinical Oncology (2006)

15506 Background: To investigate the pattern of local failure and explore any dose-response effect in locally recurred NPC patients treated by 2DRT. Methods: Based on a retrospective review on 2DRT-planned, non-metastatic NPC patients treated between 1996–99, 50 patients had local recurrence (LR). Computer tomography (CT) images at primary treatment and at LR were co-registered for each patient. The pre-treatment gross tumor volumes (GTV) and LR volumes were mapped, and 3-dimensional (3D)dosimetric reconstruction were performed. 20 patients were excluded due to insufficient data. All patients (n = 30) were treated with 2DRT (median dose 66 Gy), and 15 received additional external boost (median dose 20 Gy). The 66 Gy isodose level (IL) was taken as prescription reference. Patterns of LR were classified according to the table below. Comparisons of mean dose (D mean) between LR volume and non-recurrent GTV (GTV-LR) were performed using Wilcoxon signed ranks test. Results: The proportion of within-field (IF) failure, marginal failure, and outside-field failure for the entire cohort were 83.3% (25/30), 13.3% (4/30), and 3.3% (1/30), respectively. Elements of sub-optimal target coverage and radiographic miss were identified in 13.3% (4/30) and 16.6% (5/30) of patients, respectively. The D mean within the non-recurrent GTV was statistically higher than that in the LR volume (73.3 Gy v.s. 69.9 Gy, p = 0.037). Conclusions: Improvement in target localization or dose distribution alone can only avoid less than 20% of local failure that is attributable to radiographic miss or sub-optimal target coverage. Within-field failure was the predominant mode of local recurrence. The dose-response effect observed in this study is hypothesis-generating and forms the background for future randomized trials to verify the dose-escalation benefit using modern radiotherapy technique with high conformal capacity. [Table: see text] No significant financial relationships to disclose.
Застосування препаратів 5-аміносаліцилової кислоти в лікуванні запальних захворювань кишечника
Authors: Yu.M. Stepanov, M.V. Stoykevich, O.V. Sorochan
Journal: GASTROENTEROLOGY (2016)

Стаття присвячена порівняльній характеристиці різних похідних 5-аміносаліцилової кислоти. Дослідження останніх десятиліть змінили уявлення про можливості застосування аміносаліцилатів у терапії різних запальних захворювань кишечника. У зв’язку з невідомою етіологією хвороби Крона та неспецифічного виразкового коліту етіотропної терапії цих захворювань немає. Сутність лікування зводиться до гальмування активності запалення при загостреннях і проведенні курсів протирецидивної терапії. Численні дослідження, проведені протягом останніх 20 років, показали, що основу базисної терапії хронічних неспецифічних запальних захворювань кишечника становлять препарати 5-аміносаліцилової кислоти, або саліцилати. При виборі лікарської форми слід ураховувати відмінності між препаратами месалазину залежно від типу оболонки. Показано, що з точки зору фармакокінетики найбільш ефективними лікарськими формами месалазину для лікування неспецифічного виразкового коліту та хвороби Крона з ураженням товстої кишки є таблетки з кишковорозчинним покриттям, що забезпечує рН-залежне поступове вивільнення 5-аміносаліцилової кислоти на протязі усієї товстої кишки. Наявні на сьогодні на фармацевтичному ринку препарати 5-аміносаліцилової кислоти здатні контролювати перебіг виразкового коліту та хвороби Крона з ураженням товстої кишки в переважної більшості пацієнтів. Застосування препаратів 5-аміносаліцилової кислоти не обмежується терапією неспецифічного виразкового коліту та хвороби Крона. Препарат широко застосовується при інших захворюваннях кишечника, таких як дивертикулярна хвороба товстої кишки, банальні коліти, променеві ураження ободової кишки, а також для лікування такої поширеної хвороби, як синдром подразненого кишечника. Результати дослідження, що було проведено у відділенні захворювань кишечника ДУ «Інститут гастроентерології НАМН України» упродовж 2 років, показали позитивний ефект 20-денного лікування Месаколом неускладненої дивертикулярної хвороби. Месакол у дозі 1600 мг на добу призвів до повного купірування абдомінальної симптоматики у 68,7 % хворих.
Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation.
Authors: Susana R Marino, Sang M Lee, T Andrew Binkowski, Michael D Haagenson, Martin Maiers, Stephen Spellman, Koen van Besien, Stephanie J Lee, Theodore Karrison, Andrew Artz
Journal: Blood (2012)
Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells
Authors: Krzysztof Giannopoulos, Joanna Zaleska, Katarzyna Skorka, Malgorzata Zajac, Agnieszka Piechnik, Marta Karp, Maciej Grzywnowicz, Waldemar Tomczak, Paulina Wlasiuk, Anna Dmoszynska
Journal: Blood (2013)
Selective targeting of mutant adenomatous polyposis coli ( <i>APC</i> ) in colorectal cancer
Authors: Lu Zhang, Panayotis C. Theodoropoulos, Ugur Eskiocak, Wentian Wang, Young-Ah Moon, Bruce Posner, Noelle S. Williams, Woodring E. Wright, Sang Bum Kim, Deepak Nijhawan, Jef K. De Brabander, Jerry W. Shay
Journal: Science Translational Medicine (2016)

A small molecule specifically kills cancer cells with APC truncations and spares cells with wild-type APC.
The Proportion of Natural Regulatory T-Cells CD4+CD25+Foxp3+ in Chronic Phase Chronic Myelogenous Leukemia Patients Correlates with Sokal Score at Diagnosis and Is Increased during Imatinib Mesylate Treatment.
Authors: Emmanuel Bachy, Janine Bernaud, Pascal Roy, Dominique Rigal, Franck E. Nicolini
Journal: Blood (2007)
Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope
Authors: Paolo Prandoni, Anthonie W.A. Lensing, Martin H. Prins, Maurizio Ciammaichella, Marica Perlati, Nicola Mumoli, Eugenio Bucherini, Adriana Visonà, Carlo Bova, Davide Imberti, Stefano Campostrini, Sofia Barbar
Journal: New England Journal of Medicine (2016)

The prevalence of pulmonary embolism among patients hospitalized for syncope is not well documented, and current guidelines pay little attention to a diagnostic workup for pulmonary embolism in these patients.We performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative explanations for the syncope. The diagnosis of pulmonary embolism was ruled out in patients who had a low pretest clinical probability, which was defined according to the Wells score, in combination with a negative d-dimer assay. In all other patients, computed tomographic pulmonary angiography or ventilation-perfusion lung scanning was performed.A total of 560 patients (mean age, 76 years) were included in the study. A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patients (58.9%) on the basis of the combination of a low pretest clinical probability of pulmonary embolism and negative d-dimer assay. Among the remaining 230 patients, pulmonary embolism was identified in 97 (42.2%). In the entire cohort, the prevalence of pulmonary embolism was 17.3% (95% confidence interval, 14.2 to 20.5). Evidence of an embolus in a main pulmonary or lobar artery or evidence of perfusion defects larger than 25% of the total area of both lungs was found in 61 patients. Pulmonary embolism was identified in 45 of the 355 patients (12.7%) who had an alternative explanation for syncope and in 52 of the 205 patients (25.4%) who did not.Pulmonary embolism was identified in nearly one of every six patients hospitalized for a first episode of syncope. (Funded by the University of Padua; PESIT ClinicalTrials.gov number, NCT01797289 .).
Tacrolimus Concentrations in Hematopoetic Stem Cell Transplantation Patients Are Related to Cytochrome P450 3A5 Gene Polymorphisms.
Authors: Koichiro Kobayashi, Masahiro Ogasawara, Misato Kikuchi, Satoru Kimura, Takayoshi Miyazono, Masanobu Nakata, Kiyotoshi Imai, Teiichi Hirano, Naoki Kobayashi, Yoshio Kiyama, Junji Tanaka, Masahiro Imamura, Mitsune Tanimoto, Masaharu Kasai
Journal: Blood (2006)
Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain
Authors: Carlos A. Ramos, Barbara Savoldo, Enli Liu, Adrian P. Gee, Zhuyong Mei, Bambi J. Grilley, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti
Journal: Blood (2013)
Proposal of New Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
Authors: Shinkyo Yoon, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Sang-wook Lee, Chan-Jeoung Park, Chan-Sik Park, Jooryung Huh, Cheolwon Suh
Journal: Blood (2014)
Economic Evaluation of Quality Improvement Interventions for Bloodstream Infections Related to Central Catheters
Authors: Teryl K. Nuckols, Emmett Keeler, Sally C. Morton, Laura Anderson, Brian Doyle, Marika Booth, Roberta Shanman, Jonathan Grein, Paul Shekelle
Journal: JAMA Internal Medicine (2016)

Although quality improvement (QI) interventions can reduce central-line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI), their economic value is uncertain.